URO TODAY: Current prostate cancer tests are not good enough to enable doctors to decide which patients should be left to active surveillance, a German study suggests. READ MORE>
This study points out the difficulty in choosing the appropriate patients to counsel regarding active surveillance. Clearly the current diagnostic tests are not adequate. Should the current prognostic factors be combined with new tests such PCA-3?